PubRank

M A O'Donnell

Author PubWeight™ 30.14‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999 2.38
2 The transmembrane glycoprotein of human immunodeficiency virus type 1 induces syncytium formation in the absence of the receptor binding glycoprotein. J Virol 1992 1.29
3 NEMO/IKKgamma regulates an early NF-kappaB-independent cell-death checkpoint during TNF signaling. Cell Death Differ 2009 1.27
4 Research on drinking locations of alcohol-impaired drivers: implications for prevention policies. J Public Health Policy 1985 1.27
5 IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol 1999 1.22
6 Specificity and idiotypic analysis of a monoclonal anti-Sm antibody with anti-DNA activity. J Immunol 1985 1.20
7 Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity. Clin Exp Immunol 2003 1.12
8 Clinical and pathological characteristics of micropapillary transitional cell carcinoma: a highly aggressive variant. J Urol 2000 1.07
9 Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol 2004 1.04
10 Co-expression of interleukin-2 and green fluorescent protein reporter in mycobacteria: in vivo application for monitoring antimycobacterial immunity. Mol Immunol 2000 1.03
11 Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 2001 1.03
12 A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein. Clin Diagn Lab Immunol 1996 1.01
13 Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J Immunol 1997 1.00
14 BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation. J Urol 2000 0.94
15 Regulation of the anti-Sm autoantibody response in systemic lupus erythematosus mice by monoclonal anti-Sm antibodies. J Clin Invest 1990 0.93
16 Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol 2007 0.92
17 Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis. J Urol 1998 0.90
18 Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 1998 0.90
19 Superficial bladder cancer: the role of interferon-alpha. J Urol 1998 0.89
20 An in vivo comparison of bacillus Calmette-Guérin (BCG) and cytokine-secreting BCG vaccines. Immunology 1999 0.87
21 Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-gamma, which inhibits B16F10 melanoma cell growth in vitro. Cancer Immunol Immunother 1996 0.85
22 Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity. Clin Exp Immunol 2014 0.84
23 An analysis of lactose permease "sugar specificity" mutations which also affect the coupling between proton and lactose transport. II. Second site revertants of the thiodigalactoside-dependent proton leak by the Val177/Asn319 permease. J Biol Chem 1991 0.82
24 Prostate cancer screening: role of the digital rectal examination and prostate-specific antigen. Ann Surg Oncol 1994 0.81
25 Susceptibility to cell death induced by mutant SV40 T-antigen correlates with Purkinje neuron functional development. Mol Cell Neurosci 1997 0.79
26 Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma. J Urol 1999 0.79
27 Interleukin-12. Opportunities for the treatment of bladder cancer. Urol Clin North Am 2000 0.79
28 Interferon alpha for the treatment of superficial bladder cancer. Adv Exp Med Biol 1999 0.77
29 A painful knee in an immunocompromised patient. Postgrad Med J 1997 0.75
30 Transitional cell carcinoma--tantalizing issues of tumor biology. J Urol 1996 0.75
31 Coexpression of a nonsyncytium inducer HIV-1 glycoprotein inhibits syncytium formation by another HIV-1 Env protein. Virology 1996 0.75
32 Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B. J Urol 1997 0.75
33 Selection and enrichment of B cells from lymphoid tissues. Methods Mol Biol 2001 0.75